• Allred DC, Harvey JM, Berardo M, Clark GM. 1998. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155168.
  • Cobb BS, Morales-Alcelay S, Kleiger G, Brown KE, Fisher AG, Smale ST. 2000. Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding. Genes Dev 14:21462160.
  • Detterbeck FC, Boffa DJ, Tanoue LT. 2009. The new lung cancer staging system. Chest 136:260271.
  • Georgopoulos K. 2002. Haematopoietic cell-fate decisions, chromatin regulation and ikaros. Nat Rev Immunol 2:162174.
  • Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S, Sharpe A. 1994. The Ikaros gene is required for the development of all lymphoid lineages. Cell 79:143156.
  • Georgopoulos K, Moore DD, Derfler B. 1992. Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. Science 258:808812.
  • Georgopoulos K, Winandy S, Avitahl N. 1997. The role of the Ikaros gene in lymphocyte development and homeostasis. Annu Rev Immunol 15:155176.
  • Gonzalgo ML, Jones PA. 1997. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res 25:25292531.
  • He LC, Gao FH, Xu HZ, Zhao S, Ma CM, Li J, Zhang S, Wu YL. 2012. Ikaros inhibits proliferation and, through upregulation of Slug, increases metastatic ability of ovarian serous adenocarcinoma cells. Oncol Rep 28:13991405.
  • Kishihara K, Penninger J, Wallace VA, Kündig TM, Kawai K, Wakeham A, Timms E, Pfeffer K, Ohashi PS, Thomas ML, Furlonger C, Paige CJ, Mak TW. 1993. Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell 74:143156.
  • Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. 2010. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28:53115320.
  • Lennes IT, Lynch TJ. 2009. Quality indicators in cancer care: development and implementation for improved health outcomes in non-small-cell lung cancer. Clin Lung Cancer 10:341346.
  • Lu F, Zhang HT. 2011. DNA methylation and nonsmall cell lung cancer. Anat Rec 294:17871795.
  • Ma Z, Liu Z, Wu RF, Terada LS. 2010. p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior. Oncogene 29:55595567.
  • Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, Gerald WL, Travis WD. 2008. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 32:810827.
  • Rebollo A, Schmitt C. 2003. Ikaros, Aiolos and Helios: transcription regulators and lymphoid malignancies. Immunol Cell Biol 81:171175.
    Direct Link:
  • Taylor SM, Jones PA. 1979. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 17:771779.
  • Virely C, Moulin S, Cobaleda C, Lasgi C, Alberdi A, Soulier J, Sigaux F, Chan S, Kastner P, Ghysdael J. 2010. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia 24:12001204.
  • Xiang Y, Zhou X, Hewitt SL, Skok JA, Garrard WT. 2011. A multifunctional element in the mouse Igkappa locus that specifies repertoire and Ig loci subnuclear location. J Immunol 186:53565366.
  • Yang L, Luo Y, Wei J. 2010. Integrative genomic analyses on Ikaros and its expression related to solid cancer prognosis. Oncol Rep 24:571577.